Quoin Pharmaceuticals Ltd.: stockholders equity
Stockholders equity for Quoin Pharmaceuticals Ltd. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Quoin Pharmaceuticals Ltd. financial histories
What this measure means
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
Exact concept: us-gaap:StockholdersEquity. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2018-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 13,119,906 | USD | 2026-03-26 | 10-K · 0001104659-26-035251 |
| At date | 2024-12-31 | 9,204,673 | USD | 2026-03-26 | 10-K · 0001104659-26-035251 |
| At date | 2023-12-31 | 5,664,016 | USD | 2026-03-26 | 10-K · 0001104659-26-035251 |
| At date | 2022-12-31 | 7,406,774 | USD | 2025-03-13 | 10-K · 0001410578-25-000336 |
| At date | 2021-12-31 | 657,032 | USD | 2024-03-14 | 10-K · 0001410578-24-000198 |
| At date | 2020-12-31 | -6,607,297 | USD | 2023-03-15 | 10-K · 0001410578-23-000267 |
| At date | 2019-12-31 | -4,511,933 | USD | 2022-04-14 | 20-F · 0001104659-22-045620 |
| At date | 2018-12-31 | -2,951,532 | USD | 2022-04-14 | 20-F · 0001104659-22-045620 |
Related financial histories
- Quoin Pharmaceuticals Ltd.: total assets
- Quoin Pharmaceuticals Ltd.: total liabilities
- Quoin Pharmaceuticals Ltd.: cash and cash equivalents
- Quoin Pharmaceuticals Ltd.: net income or loss
- Quoin Pharmaceuticals Ltd.: operating cash flow
- Quoin Pharmaceuticals Ltd.: contract revenue excluding tax
- Quoin Pharmaceuticals Ltd.: financing cash flow
- Quoin Pharmaceuticals Ltd.: investing cash flow
- Quoin Pharmaceuticals Ltd.: retained earnings or deficit
- Quoin Pharmaceuticals Ltd.: basic weighted-average shares
- Quoin Pharmaceuticals Ltd.: diluted weighted-average shares
- Quoin Pharmaceuticals Ltd.: basic earnings per share
- Quoin Pharmaceuticals Ltd.: diluted earnings per share
- Quoin Pharmaceuticals Ltd.: share-based compensation expense
- Quoin Pharmaceuticals Ltd.: current assets
- Quoin Pharmaceuticals Ltd.: current liabilities
- Quoin Pharmaceuticals Ltd.: current accounts payable
- Quoin Pharmaceuticals Ltd.: net finite-lived intangible assets
- Quoin Pharmaceuticals Ltd.: selling, general and administrative expense
- Quoin Pharmaceuticals Ltd.: research and development expense
Inspect the source
- Entity
- Quoin Pharmaceuticals Ltd. / CIK 0001671502
- Captured
- 2026-09-21T17:23:21.592Z
- SEC response SHA-256
2151f8b73d57a6fe9ca2f61e800771e9f36346bab50baeb75ac206654fb0a978
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001671502.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))